Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback